(Q36634261)

15 August 2017

1 reference

title

Therapeutic options to target angiogenesis in human malignancies (English)

1 reference

15 August 2017

1

Roy S Herbst

1 reference

PubMed ID

17064223

15 August 2017

language of work or name

English

0 references

publication date

1 November 2006

1 reference

Expert Opinion on Emerging Drugs

15 August 2017

16

1 reference

based on heuristic

inferred from page(s)

published in

1 reference

15 August 2017

11

1 reference

15 August 2017

635-650

1 reference

15 August 2017

4

1 reference

Mechanisms of angiogenesis and arteriogenesis

15 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.4.635

Angiogenesis in cancer, vascular, rheumatoid and other disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.4.635

Tumor angiogenesis: therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.4.635

Angiogenesis in cancer and other diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.4.635

Matrix metalloproteinases regulate neovascularization by acting as pericellular fibrinolysins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.4.635

Angiogenesis as a therapeutic target

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.4.635

Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.4.635

The biology of vascular endothelial growth factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.4.635

Vascular-specific growth factors and blood vessel formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.4.635

VEGF and the quest for tumour angiogenesis factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.4.635

The biology of VEGF and its receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.4.635

HIF hydroxylation and the mammalian oxygen-sensing pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.4.635

VEGF receptor signaling in tumor angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.4.635

VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.4.635

Angiogenesis-independent endothelial protection of liver: role of VEGFR-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.4.635

Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.4.635

Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.4.635

Vascular endothelial growth factor signaling pathway as an emerging target in hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.4.635

Vascular endothelial growth factor (VEGF) mRNA isoform expression pattern is correlated with liver metastasis and poor prognosis in colon cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.4.635

A high vascular count and overexpression of vascular endothelial growth factor are associated with unfavourable prognosis in operated small cell lung carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.4.635

Clinical implications of expression of vascular endothelial growth factor in metastatic lesions of ovarian cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.4.635

Vascular endothelial growth factor expression in early stage ovarian carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.4.635

Autocrine stimulation of VEGFR-2 activates human leukemic cell growth and migration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.4.635

Pericyte loss and microaneurysm formation in PDGF-B-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.4.635

Autocrine PDGFR signaling promotes mammary cancer metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.4.635

Angiopoietins in tumours: the angiogenic switch

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.4.635

Suppression of angiogenesis and tumor growth by selective inhibition of angiopoietin-2

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.4.635

Expression and significance of Tie-1 and Tie-2 receptors, and angiopoietins-1, 2 and 4 in colorectal adenocarcinoma: Immunohistochemical analysis and correlation with clinicopathological factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.4.635

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.4.635

A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.4.635

Cancer and Leukemia Group B 90206: A randomized phase III trial of interferon-alpha or interferon-alpha plus anti-vascular endothelial growth factor antibody (bevacizumab) in metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.4.635

Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.4.635

Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lun

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.4.635

Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.4.635

Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.4.635

Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.4.635

Intensive therapy with growth factor support for patients with Ewing tumor metastatic at diagnosis: Pediatric Oncology Group/Children's Cancer Group Phase II Study 9457--a report from the Children's Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.4.635

VEGF-Trap: a VEGF blocker with potent antitumor effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.4.635

Potent VEGF blockade causes regression of coopted vessels in a model of neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.4.635

Vascular endothelial growth factor trap combined with paclitaxel strikingly inhibits tumor and ascites, prolonging survival in a human ovarian cancer model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.4.635

SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.4.635

Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.4.635

Efficacy of the kinase inhibitor SU11248 against gastrointestinal stromal tumor mutants refractory to imatinib mesylate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.4.635

Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.4.635

Sunitinib in patients with metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.4.635

Randomized phase II trial of pemetrexed combined with either cisplatin or carboplatin in untreated extensive-stage small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.4.635

Phase I clinical and pharmacokinetic study of PTK/ZK, a multiple VEGF receptor inhibitor, in patients with liver metastases from solid tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.4.635

A multicenter phase II trial of ZD6474, a vascular endothelial growth factor receptor-2 and epidermal growth factor receptor tyrosine kinase inhibitor, in patients with previously treated metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.4.635

Clinical evaluation of ZD6474, an orally active inhibitor of VEGF and EGF receptor signaling, in patients with solid, malignant tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.4.635

Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.4.635

Optimal locoregional treatment in gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.4.635

AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.4.635

Dual inhibition of the epidermal growth factor and vascular endothelial growth factor phosphorylation for antivascular therapy of human prostate cancer in the prostate of nude mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.4.635

Tissue levels of matrix metalloproteinases MMP-2 and MMP-9 are related to the overall survival of patients with gastric carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.4.635

A phase I study of oral BMS-275291, a novel nonhydroxamate sheddase-sparing matrix metalloproteinase inhibitor, in patients with advanced or metastatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.4.635

A randomized phase II trial of the matrix metalloproteinase inhibitor BMS-275291 in hormone-refractory prostate cancer patients with bone metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.4.635

Properties of thalidomide and its analogues: implications for anticancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.4.635

Endostatin: the logic of antiangiogenic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.4.635

Epidermal growth factor inhibition in solid tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.4.635

Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.4.635

Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.4.635

Surrogate markers in antiangiogenesis clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.4.635

Quantification of angiogenesis in solid human tumours: an international consensus on the methodology and criteria of evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.4.635

Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer a

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.4.635

Effect of p53 status on tumor response to antiangiogenic therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.4.635

AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.4.635

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.4.635

Integrin β4 signaling promotes tumor angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.4.635

Vascular endothelial growth factor is of high prognostic value in node-negative breast carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.4.635

VASCULAR ENDOTHELIAL GROWTH FACTOR AS PROGNOSTIC FACTOR IN RENAL CELL CARCINOMA

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.4.635

10.1517/14728214.11.4.635

21 January 2018

Identifiers

DOI

1 reference

15 August 2017

1 reference

PubMed ID

17064223